

Ezequiel Ridruejo

List of Publications by Citations

Source: <https://exaly.com/author-pdf/3985835/ezequiel-ridruejo-publications-by-citations.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

79
papers

2,374
citations

19
h-index

47
g-index

97
ext. papers

2,930
ext. citations

4.9
avg, IF

4.58
L-index

#	Paper	IF	Citations
79	Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. <i>The Lancet Gastroenterology and Hepatology</i> , 2017 , 2, 161-176	18.8	1196
78	The present and future disease burden of hepatitis C virus (HCV) infections with today's treatment paradigm - volume 2. <i>Journal of Viral Hepatitis</i> , 2015 , 22 Suppl 1, 26-45	3.4	100
77	Historical epidemiology of hepatitis C virus (HCV) in select countries - volume 2. <i>Journal of Viral Hepatitis</i> , 2015 , 22 Suppl 1, 6-25	3.4	82
76	Imatinib-induced fatal acute liver failure. <i>World Journal of Gastroenterology</i> , 2007 , 13, 6608-111	5.6	65
75	Efficacy and safety of long term entecavir in chronic hepatitis B treatment naïve patients in clinical practice. <i>Annals of Hepatology</i> , 2014 , 13, 327-336	3.1	56
74	The Latin American Association for the Study of the Liver (ALEH) position statement on the redefinition of fatty liver disease. <i>The Lancet Gastroenterology and Hepatology</i> , 2021 , 6, 65-72	18.8	55
73	The liver in times of COVID-19: What hepatologists should know. <i>Annals of Hepatology</i> , 2020 , 19, 353-358	3.1	46
72	Treatment with direct-acting antivirals for HCV decreases but does not eliminate the risk of hepatocellular carcinoma. <i>Liver International</i> , 2019 , 39, 1033-1043	7.9	40
71	Strategies to manage hepatitis C virus (HCV) infection disease burden - volume 2. <i>Journal of Viral Hepatitis</i> , 2015 , 22 Suppl 1, 46-73	3.4	37
70	Etiology of hepatocellular carcinoma in Latin America: a prospective, multicenter, international study. <i>Annals of Hepatology</i> , 2010 , 9, 63-69	3.1	35
69	Efficacy, tolerability and safety in the treatment of chronic hepatitis C with combination of PEG-Interferon + Ribavirin in daily practice. <i>Annals of Hepatology</i> , 2010 , 9, 46-51	3.1	35
68	Breath-ammonia testing of healthy subjects and patients with cirrhosis. <i>Digestive Diseases and Sciences</i> , 2012 , 57, 189-95	4	29
67	Central hypothyroidism and hypophysitis during treatment of chronic hepatitis C with pegylated interferon alpha and ribavirin. <i>European Journal of Gastroenterology and Hepatology</i> , 2006 , 18, 693-4	2.2	26
66	Relapse rates in chronic hepatitis B naïve patients after discontinuation of antiviral therapy with entecavir. <i>Journal of Viral Hepatitis</i> , 2014 , 21, 590-6	3.4	24
65	Disease Progression in Patients With Hepatitis C Virus Infection Treated With Direct-Acting Antiviral Agents. <i>Clinical Gastroenterology and Hepatology</i> , 2020 , 18, 2554-2563.e3	6.9	21
64	Severe cholestatic hepatitis as the first symptom of secondary syphilis. <i>Digestive Diseases and Sciences</i> , 2004 , 49, 1401-4	4	21
63	Acute cholestatic hepatitis after reinitiating treatment with atorvastatin. <i>Journal of Hepatology</i> , 2002 , 37, 165-6	13.4	21

62	Genetic variation in Interleukin-28B predicts SVR in hepatitis C genotype 1 Argentine patients treated with PEG IFN and ribavirin. <i>Annals of Hepatology</i> , 2011 , 10, 452-457	3.1	20
61	Etiology of hepatocellular carcinoma in Latin America: a prospective, multicenter, international study. <i>Annals of Hepatology</i> , 2010 , 9, 63-9	3.1	19
60	Hepatotoxicity induced by coxibs: how concerned should we be?. <i>Expert Opinion on Drug Safety</i> , 2016 , 15, 1463-1475	4.1	18
59	Outcome of COVID-19 in Patients With Autoimmune Hepatitis: An International Multicenter Study. <i>Hepatology</i> , 2021 , 73, 2099-2109	11.2	18
58	Latin American Association for the Study of the Liver (LAASL) Clinical Practice Guidelines: Management of Hepatocellular Carcinoma. <i>Annals of Hepatology</i> , 2014 , 13, S4-S40	3.1	17
57	Effectiveness of entecavir in chronic hepatitis B NUC-naïve patients in routine clinical practice. <i>International Journal of Clinical Practice</i> , 2011 , 65, 866-70	2.9	17
56	Short and long term outcome of kidney transplanted patients with chronic viral hepatitis B and C. <i>Annals of Hepatology</i> , 2010 , 9, 271-277	3.1	16
55	Fatty liver disease, an emerging etiology of hepatocellular carcinoma in Argentina. <i>World Journal of Hepatology</i> , 2018 , 10, 41-50	3.4	16
54	Antiviral treatment for chronic hepatitis B in renal transplant patients. <i>World Journal of Hepatology</i> , 2015 , 7, 189-203	3.4	16
53	Treatment of chronic hepatitis B in clinical practice with entecavir or tenofovir. <i>World Journal of Gastroenterology</i> , 2014 , 20, 7169-80	5.6	15
52	Latin American Association for the Study of the Liver (LAASL) clinical practice guidelines: management of hepatocellular carcinoma. <i>Annals of Hepatology</i> , 2014 , 13 Suppl 1, S4-40	3.1	15
51	Direct-Acting Antiviral Agents for HCV-Associated Glomerular Disease and the Current Evidence. <i>Pathogens</i> , 2019 , 8,	4.5	14
50	Hepatocellular carcinoma in renal transplant patients. <i>Transplantation Proceedings</i> , 2005 , 37, 2086-8	1.1	12
49	Role of HLA-DP and HLA-DQ on the clearance of hepatitis B virus and the risk of chronic infection in a multiethnic population. <i>Liver International</i> , 2017 , 37, 1476-1487	7.9	11
48	Ombitasvir/paritaprevir/ritonavir/dasabuvir ± ribavirin is safe and effective in HCV-infected patients in a real-life cohort from Latin America. <i>Journal of Medical Virology</i> , 2017 , 89, 1590-1596	19.7	11
47	Chylous ascites as the main manifestation of left ventricular dysfunction: a case report. <i>BMC Gastroenterology</i> , 2005 , 5, 25	3	11
46	Entecavir treatment for chronic hepatitis B infection in end-stage renal disease and kidney transplantation. <i>Dialysis and Transplantation</i> , 2010 , 39, 397-400		10
45	Intermediate-advanced hepatocellular carcinoma in Argentina: Treatment and survival analysis. <i>World Journal of Gastroenterology</i> , 2019 , 25, 3607-3618	5.6	10

44	Genetic variation in interleukin-28B predicts SVR in hepatitis C genotype 1 Argentine patients treated with PEG IFN and ribavirin. <i>Annals of Hepatology</i> , 2011 , 10, 452-7	3.1	10
43	Adherence to Barcelona Clinic Liver Cancer therapeutic algorithm for hepatocellular carcinoma in the daily practice: a multicenter cohort study from Argentina. <i>European Journal of Gastroenterology and Hepatology</i> , 2018 , 30, 376-383	2.2	9
42	Safety of direct-acting antivirals in the treatment of chronic hepatitis C. <i>Expert Opinion on Drug Safety</i> , 2014 , 13, 307-19	4.1	9
41	An update on the management of hepatitis C: guidelines for protease inhibitor-based triple therapy from the Latin American Association for the Study of the Liver. <i>Annals of Hepatology</i> , 2013 , 12, S3-S35	3.1	9
40	Hepatitis C virus infection and outcome of renal transplantation. <i>Transplantation Proceedings</i> , 2007 , 39, 3127-30	1.1	9
39	B.A.R.C.O.S. (Brazilian Argentine Hepatitis C Collaborative Observational Study): Effectiveness and clinical outcomes of HCV treatment with daclatasvir and sofosbuvir with or without ribavirin. <i>Journal of Viral Hepatitis</i> , 2019 , 26, 1200-1209	3.4	8
38	Rationale for treating hepatitis C virus infection in patients with mild to moderate chronic kidney disease. <i>Hemodialysis International</i> , 2018 , 22 Suppl 1, S97-S103	1.7	7
37	Predictors of response to chronic hepatitis C treatment. <i>Future Virology</i> , 2012 , 7, 1089-1101	2.4	7
36	Which Strategies Should Be Implemented in Latin America to Eradicate Hepatitis C Virus by 2030?. <i>Clinical Liver Disease</i> , 2019 , 13, 43-45	2.2	6
35	Argentinian clinical practice guideline for surveillance, diagnosis, staging and treatment of hepatocellular carcinoma. <i>Annals of Hepatology</i> , 2020 , 19, 546-569	3.1	6
34	Polymorphisms associated with resistance to protease inhibitors in naïve patients infected with hepatitis C virus genotype 1 in Argentina: Low prevalence of Q80K. <i>Virus Research</i> , 2017 , 240, 140-146	6.4	6
33	Hepatitis C virus diversification in Argentina: comparative analysis between the large city of Buenos Aires and the small rural town of O'Brien. <i>PLoS ONE</i> , 2013 , 8, e84007	3.7	6
32	Efficacy, tolerability and safety in the treatment of chronic hepatitis C with combination of PEG-Interferon - Ribavirin in daily practice. <i>Annals of Hepatology</i> , 2010 , 9, 46-51	3.1	6
31	Short and long term outcome of kidney transplanted patients with chronic viral hepatitis B and C. <i>Annals of Hepatology</i> , 2010 , 9, 271-7	3.1	6
30	The ECHO model proved to be a useful tool to increase clinicians' self-effectiveness for care of patients with Hepatitis C in Argentina. <i>Journal of Viral Hepatitis</i> , 2019 , 26, 1284-1292	3.4	5
29	Hepatitis C virus genotype 1 infection: Prevalence of NS5A and NS5B resistance-associated substitutions in naïve patients from Argentina. <i>Journal of Medical Virology</i> , 2019 , 91, 1970-1978	19.7	5
28	Pre-treatment prediction of response to peginterferon plus ribavirin in chronic hepatitis C genotype 3. <i>World Journal of Hepatology</i> , 2015 , 7, 703-9	3.4	5
27	Surveillance for Hepatocellular Carcinoma: Does the Place Where Ultrasound Is Performed Impact Its Effectiveness?. <i>Digestive Diseases and Sciences</i> , 2019 , 64, 718-728	4	5

26	Clinical epidemiology of acute hepatitis C in South America. <i>Journal of Medical Virology</i> , 2017 , 89, 276-283	3.7	4
25	Entecavir in the treatment of chronic hepatitis B in kidney transplantation. <i>Journal of Hepatology</i> , 2012 , 56, 997-8; author reply 999	13.4	4
24	Virological breakthrough and resistance in patients with chronic hepatitis B receiving nucleos(t)ide analogues in clinical practice. <i>Hepatology</i> , 2011 , 54, 1104-5; author reply 1105	11.2	4
23	Thioctic acid-induced acute cholestatic hepatitis. <i>Annals of Pharmacotherapy</i> , 2011 , 45, e43	2.9	4
22	NS3 genomic sequencing and phylogenetic analysis as alternative to a commercially available assay to reliably determine hepatitis C virus subtypes 1a and 1b. <i>PLoS ONE</i> , 2017 , 12, e0182193	3.7	4
21	Decompensated cirrhosis and liver transplantation negatively impact in DAA treatment response: Real-world experience from HCV-LALREAN cohort. <i>Journal of Medical Virology</i> , 2020 , 92, 3545	19.7	4
20	Hepatitis B virus infection as a risk factor for chronic kidney disease. <i>Expert Review of Clinical Pharmacology</i> , 2019 , 12, 867-874	3.8	3
19	Does hepatitis B virus therapy reduce the risk of hepatocellular carcinoma?. <i>Expert Opinion on Drug Safety</i> , 2015 , 14, 439-51	4.1	3
18	Effectiveness of hepatitis C treatment with pegylated interferon and ribavirin in urban minority patients. <i>Hepatology</i> , 2010 , 51, 2231; author reply 2231-2	11.2	3
17	Effects of Immunosuppressive Drugs on COVID-19 severity in Patients with Autoimmune Hepatitis. <i>Liver International</i> , 2021 ,	7.9	3
16	Hepatitis C virus infection in Argentina: Burden of chronic disease. <i>World Journal of Hepatology</i> , 2016 , 8, 649-58	3.4	3
15	Serious liver injury induced by Nimesulide: an international collaborative study. <i>Archives of Toxicology</i> , 2021 , 95, 1475-1487	5.8	3
14	Prevalence of hepatitis C virus infection according to the year of birth: identification of risk groups. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2018 , 37, 247-254	5.3	2
13	Efficacy and safety of direct-acting antiviral agents for HCV in mild-to-moderate chronic kidney disease. <i>Nefrologia</i> , 2020 , 40, 46-52	1.5	2
12	Hepatitis E infection is an infrequent cause of acute hepatitis in the metropolitan area of Buenos Aires. <i>Journal of Clinical Virology</i> , 2020 , 126, 104309	14.5	1
11	Efficacy and safety of direct-acting antiviral agents for HCV in mild-to-moderate chronic kidney disease. <i>Nefrologia</i> , 2020 , 40, 46-52	0.4	1
10	Syncope during boceprevir treatment in hepatitis C. <i>Annals of Hepatology</i> , 2013 , 12, 837-838	3.1	1
9	Treatment of chronic hepatitis C with pegylated interferon and ribavirin in treatment-naive patients in <i>True life</i> <i>European Journal of Gastroenterology and Hepatology</i> , 2011 , 23, 195	2.2	1

8	Hepatitis C treatment completion rates in routine clinical care. <i>Liver International</i> , 2010 , 30, 1082; author reply 1083	7.9	1
7	Polymyalgia rheumatica presenting as acute cholestatic hepatitis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2005 , 20, 801-2	4	1
6	An Update on Hepatocellular Carcinoma in Chronic Kidney Disease. <i>Cancers</i> , 2021 , 13,	6.6	1
5	Hepatitis C virus treatment failure: Clinical utility for testing resistance-associated substitutions. <i>World Journal of Hepatology</i> , 2021 , 13, 1069-1078	3.4	0
4	Direct-acting antiviral treatment failure in genotype 2 hepatitis C chronic infection. <i>Journal of Viral Hepatitis</i> , 2021 , 28, 446-447	3.4	
3	Reply. <i>Clinical Gastroenterology and Hepatology</i> , 2021 , 19, 623-624	6.9	
2	Simplified treatment of hepatitis C: another strategy to overcome the barriers to its elimination. <i>Medicina</i> , 2021 , 81, 252-256	1	
1	TGF- β mediates cell proliferation and development of hepatocarcinogenesis by downregulating deiodinase 1 expression. <i>Medicina</i> , 2021 , 81, 346-358	1	